Compare MRKR & BESS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRKR | BESS |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 16.8M |
| IPO Year | 2010 | 2022 |
| Metric | MRKR | BESS |
|---|---|---|
| Price | $1.00 | $2.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $7.87 | ★ $9.75 |
| AVG Volume (30 Days) | ★ 168.4K | 98.3K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.61 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $168,880.00 |
| Revenue This Year | $19.61 | N/A |
| Revenue Next Year | $375.85 | $206.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.84 | $1.52 |
| 52 Week High | $2.46 | $6.45 |
| Indicator | MRKR | BESS |
|---|---|---|
| Relative Strength Index (RSI) | 45.81 | 51.93 |
| Support Level | $0.88 | $2.03 |
| Resistance Level | $1.32 | $2.46 |
| Average True Range (ATR) | 0.12 | 0.23 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 31.33 | 82.84 |
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Bimergen Energy Corp is a renewable energy project developer that enables the clean energy transition and provides critical grid stability via solutions across a range of applications through portfolio of utility-scale Battery Energy Storage System (BESS) and solar development projects. Its portfolio includes approximately 23 development-stage utility-scale BESS projects with a projected total storage capacity of around 1.965 gigawatts (GW) and approximately 13 development-stage solar energy projects expected to generate around 1.640 GW upon completion and operation.